nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.10.2008 | Research Paper

E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas

verfasst von: Alan Wells, Clayton Yates, Christopher R. Shepard

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Cancer metastasis follows a sequential series of events, and many of the critical steps are distinctly similar to EMT-like transformations that occur during normal embryonic development. A current area of focus is the similarities between how cancer cells interact with the ectopic parenchyma after metastatic spread, and secondary developmental MET events that occur in epithelial tissues that have re-assembled within the embryo from mesenchymal cells. Accumulating evidence suggests a critical role for these secondary events, termed mesenchymal-epithelial transitions (MET) in development and mesenchymal-epithelial reverting transitions (MErT) in cancer. In this situation, metastatic seed cancer cells may inertly become part of the ectopic tissue and therefore surmount the metastatic inefficiencies to which most disseminated cancer cells succumb. Just as a critical EMT event is the downregulation or silencing of E-cadherin, we discuss the role of E-cadherin in cancer-associated MErT at distant metastatic sites and speculate on the implications for the fate of micrometastases that undergo a transition to being E-cadherin positive.

Babu M, Wells A (2001) Dermal-epidermal communication in wound healing. Wounds 13:183–189

Birchmeier C, Birchmeier W, Gherardi E, VandeWoude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925PubMedCrossRef

Boccaccio C, Comoglio PM (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6:637–645PubMedCrossRef

Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66:8319–8326PubMedCrossRef

Christofori G (2006) New signals from the invasive front. Nature 441:444–450PubMedCrossRef

Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, Ben-Ze’ev A (2003) Autoregulation of E-cadherin expression by cadherin–cadherin interactions: the roles of b-catenin signaling, Slug, and MAPK. J Cell Biol 163:847–857PubMedCrossRef

Cristofanilli M, Budd GT et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791PubMedCrossRef

Ewing J (1922) Tumors of the prostate. Neoplastic diseases. WB Saunders Company, Philadelphia, pp 784–785

Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef

10.

Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:362–374PubMedCrossRef

11.

Gleave ME, Hsieh JT, vonEschenbach AC, Chung LWK (1992) Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 147:1151–1159PubMed

12.

Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG (2000) Methylation patterns of the E-cadherin 5’CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275:2727–2732PubMedCrossRef

13.

Guarino M, Rubino B, Ballabio G (2007) The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:305–318PubMedCrossRef

14.

Gumbiner BM (2005) Regualtion of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 6:622–634PubMedCrossRef

15.

Hazan RB, Norton L (1998) The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 273:9078–9084PubMedCrossRef

16.

Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213:374–383PubMedCrossRef

17.

Imai T, Horiuchi A et al (2004) Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 35:1469–1476PubMedCrossRef

18.

Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428PubMedCrossRef

19.

Kaihara T, Kawamata H, Imura J, Fujii S, Kitajima K, Omotehara F, Maeda N, Nakamura T, Fujimori T (2003) Redifferentiation and ZO-1 reexpression in liver-metastatized colorectal cancer: possible association with epidermal growth factor receptor-induced tyrosine phosphorylation of ZO-1. Cancer Sci 94:166–172PubMedCrossRef

20.

Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784PubMed

21.

Kang H-G, Jenabi JM et al (2007) E-cadherin cell–cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res 67:3094–3105PubMedCrossRef

22.

Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:277–279. PubMedCrossRef

23.

Kim H, Turner T, Kassis J, Souto J, Wells A (1999) EGF receptor signaling in prostate development. Histol Histopathol 14:1175–1182PubMed

24.

Kopstein L, Christofori G (2006) Metastasis: cell autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 63:449–468CrossRef

25.

Kowalski PJ, Rubin MA, Kleer CG (2003) E-cadherin expression in primary carcinoma of the breast and its distant metastases. Breast Cancer Res 5:R217–R222PubMedCrossRef

26.

Luzzi KJ, MacDonald IC et al (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153:865–873PubMed

27.

Mamoune A, Kassis J et al (2004) DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling. Exp Cell Res 299:91–100PubMedCrossRef

28.

Miura H, Nishimura K et al (2001) Effects of hepatocyte growth factor on E-cadherin-mediated cell–cell adhesion in DU145 prostate cancer cells. Urology 58:1064–1069PubMedCrossRef

29.

Moustakas A, Heldin C-H (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98:1512–1520PubMedCrossRef

30.

Nelson WJ, Nusse R (2004) Convergence of wnt, b-catenin, and cadherin pathways. Science 303:1483–1487PubMedCrossRef

31.

Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:98–101PubMed

32.

Putz E, Witter K et al (1999) Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 59:241–248PubMed

33.

Reddy P, Liu L et al (2005) Formation of E-cadherin mediated cell–cell adhesion activates Akt and mitogen activated protein kinase (MAPK) via phosphatidylinositol 3 kinase and ligand-independent action of epidermal growth factor (EGF) receptor in ovarian cancer cells. Mol Endocrinol 19:2564–2578PubMedCrossRef

34.

Reynolds AB, Daniel J, McCrea PD, Wheelock MJ, Wu J, Zhang Z (1994) Identification of a new catenin: the tyrosine kinase substrate p120^cas associates with E-cadherin complexes. Mol Cell Biol 14:8333–8342PubMed

35.

Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML (2001) E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol 32:690–697PubMedCrossRef

36.

Shah RB, Mehra R et al (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases. Cancer Res 64:9209–9216PubMedCrossRef

37.

Shepard CR, Yates CC, Wells A (2007) Signaling pathway activation upon re-expression of E-cadherin in invasive breast cancer cells and interaction with ectopic normal epithelial cells (unpublished data)

38.

Simcha I, Geiger B, Yehuda-Levenberg S, Salomon D, Ben-Ze’ev A (1996) Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol 133:199–209PubMedCrossRef

39.

Stessels F, VandenEynden G et al (2004) Breast adenocarcinoma liver metastases, in contrast to colorectal liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 90:1429–1436PubMedCrossRef

40.

Strathdee G (2002) Epigenetic versus genetic alterations in the inactivation of E-cadherin Seminars. Cancer Biol 12:373–379

41.

Tarin D (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65:5996–6000PubMedCrossRef

42.

Thompson EW, Newgreen DF (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition. Cancer Res 65:5991–5995PubMedCrossRef

43.

Wells A (2000) Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 78:31–101PubMedCrossRef

44.

Yates C, Shepard CR et al (2007a) Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. Adv Cancer Res 96:225–246CrossRef

45.

Yates C, Shepard CR, Stolz DB, Wells A (2007b) Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 96:1246–1252PubMedCrossRef

46.

Yates CC, Shepard CR, Stolz DB, Wells A (2007c) Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 96:1246–1252PubMedCrossRef

47.

Yates C, Wells A, Turner T (2005) Luteinizing hormone releasing hormone (LHRH) analog reverses the cell adhesion profile of DU-145 human prostate carcinoma. Br J Cancer 92:366–375PubMed

Titel: E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas
verfasst von: Alan Wells
Clayton Yates
Christopher R. Shepard
Publikationsdatum: 01.10.2008
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 6/2008
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-008-9167-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas

Abstract

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model

Precise measurement of the E-cadherin repressor Snail in formalin-fixed endometrial carcinoma using protein lysate microarrays

Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions

Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development

The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Update Onkologie